How to Get Jardiance in Vermont: Prescriptions, Telehealth, and Pharmacy Access

What Jardiance Is and Why Vermont Patients Seek It

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA under the brand name Jardiance for three distinct indications: glycemic control in adults with type 2 diabetes, reduction of cardiovascular death and hospitalization in adults with heart failure (both reduced and preserved ejection fraction), and slowing the progression of chronic kidney disease. The FDA label is publicly searchable at accessdata.fda.gov.

Vermont has roughly 52,000 adults living with diagnosed diabetes, according to CDC state surveillance data, and a growing proportion of heart failure patients whose cardiologists are now routinely adding SGLT2 inhibitors to guideline-directed medical therapy [1]. The mechanism is straightforward: the drug blocks glucose reabsorption in the proximal tubule, lowering blood glucose independently of insulin, while also reducing intraglomerular pressure and driving mild osmotic diuresis that offloads cardiac preload.

The EMPA-REG OUTCOME trial (N=7,020) published in the New England Journal of Medicine in 2015 found that empagliflozin reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority and P=0.04 for superiority) in adults with type 2 diabetes and established cardiovascular disease [2]. That result changed prescribing behavior nationally, including in Vermont, where cardiologists and endocrinologists now frequently initiate empagliflozin outside of diabetes management entirely.

The 2023 American Diabetes Association Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of baseline HbA1c" [3].

Who Can Prescribe Jardiance in Vermont

Prescribing authority in Vermont is broad by design. MDs and DOs may prescribe empagliflozin. Nurse practitioners (NPs) in Vermont hold full practice authority under Vermont Statutes Annotated Title 26, Chapter 28, meaning they may diagnose and prescribe without physician supervision. Physician assistants (PAs) may also prescribe controlled and non-controlled medications under a practice agreement that does not require co-signature for each prescription. Any of these providers can send a Jardiance prescription electronically to a Vermont-licensed pharmacy.

Practically, this means that a cardiologist, a primary care NP, an endocrinologist, or a telehealth PA working for a Vermont-licensed platform can all legally initiate empagliflozin. The prescriber must hold a valid Vermont DEA registration (for controlled substances on the same visit) and maintain a Vermont license, but for Jardiance specifically, no DEA registration is required since empagliflozin is not a controlled substance. That single fact simplifies telehealth prescribing considerably.

The HealthRX clinical team uses a four-step prescribing checklist for Vermont empagliflozin initiations:

1. Confirm indication (type 2 diabetes, HFrEF/HFpEF, or CKD stage G3-G4).
2. Review baseline labs: eGFR must be at or above 20 mL/min/1.73m2 for the heart failure or CKD indication; the FDA label cautions against use primarily for glycemic control when eGFR is <30.
3. Screen for contraindications: dialysis dependence, recurrent genitourinary infections, active genital mycotic infections, or history of Fournier's gangrene.
4. Verify insurance or cost pathway before the visit ends so the patient has a clear plan before leaving the virtual waiting room.

How to Get a Jardiance Prescription in Vermont: Step-by-Step

Getting a prescription does not require a specialist. The process is the same whether you see a local primary care provider or a Vermont-licensed telehealth platform.

Step 1: Gather your recent labs. A basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) drawn within the past six months is the minimum. Your provider needs serum creatinine and a calculated eGFR to dose correctly and to clear you for the drug. An HbA1c result from the past three months is standard for the diabetes indication. Bring a list of current medications, especially diuretics, ACE inhibitors, ARBs, and NSAIDs, because each interacts with the drug's diuretic effect.

Step 2: Book a visit. In-person appointments at Vermont primary care clinics typically run two to four weeks out for new patients. A licensed Vermont telehealth provider can usually offer same-day or next-day scheduling. Video visits qualify under Vermont law; audio-only visits may be accepted by some platforms depending on payer type.

Step 3: Complete the clinical evaluation. The provider will review your labs, confirm your indication, and discuss dosing. The standard starting dose for most indications is empagliflozin 10 mg once daily taken in the morning, with or without food. Dose escalation to 25 mg is available for additional glycemic control in type 2 diabetes once the 10 mg dose is tolerated.

Step 4: Receive your electronic prescription. Vermont pharmacies accept e-prescriptions through Surescripts. Your provider sends the script directly to your preferred pharmacy. Most retail pharmacies in Vermont stock Jardiance 10 mg and 25 mg tablets; call ahead to confirm availability at independent pharmacies in rural areas.

Step 5: Fill and start. Take the first dose in the morning to let any osmotic diuresis run its course before bedtime. You will likely urinate more for the first one to two weeks. Stay hydrated. Scheduled follow-up labs (repeat BMP) are typically ordered at four to eight weeks.

Telehealth Prescribing for Jardiance in Vermont

Vermont's telehealth framework permits prescribing of non-controlled medications via synchronous video visit without a prior in-person examination, provided the provider can form a valid clinical judgment [4]. Empagliflozin, being a non-controlled prescription drug, fits squarely within that framework. The Vermont Department of Health maintained the telehealth prescribing rules that were expanded during the public health emergency, and Vermont Act 167 (2022) codified key telehealth provisions into permanent statute.

Several Vermont-licensed platforms now offer SGLT2 inhibitor management. When selecting a platform, verify that the prescriber holds an active Vermont medical license (searchable at the Vermont Office of Professional Regulation at sos.vermont.gov), that the platform accepts your insurance or offers transparent cash-pay pricing, and that they can coordinate prior authorization with your insurer if needed.

The EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) in patients with heart failure and reduced ejection fraction [5]. That magnitude of benefit has driven cardiologists to push for faster access pathways, including telehealth initiation for stable outpatients.

Vermont Medicaid Coverage and Prior Authorization

Vermont Medicaid (Green Mountain Care) covers empagliflozin for type 2 diabetes, heart failure, and CKD, but prior authorization (PA) is required for all three indications on the fee-for-service formulary. The PA criteria typically include documentation of the diagnosis, a recent HbA1c or eGFR, and evidence of one of the following: inadequate glycemic control on metformin for the diabetes indication, a confirmed LVEF measurement for the heart failure indication, or a urine albumin-to-creatinine ratio above 200 mg/g for the CKD indication.

Vermont Medicaid PA requests are submitted through the Vermont Health Information Exchange or via the pharmacy benefit manager's online portal. Approval typically takes two to five business days for standard requests; urgent PA requests can be processed within 24 hours when the provider documents clinical urgency. Once approved, the PA is generally valid for 12 months and must be renewed annually.

The 2022 ADA and Heart Failure Society of America joint consensus report states: "SGLT2 inhibitors should be offered to patients with type 2 diabetes and heart failure regardless of ejection fraction, absent contraindications, given the magnitude of cardiovascular and renal benefit demonstrated in randomized trials" [6]. This language is directly usable in PA appeal letters when an initial request is denied.

Commercial plans available through Vermont Health Connect (the state exchange) have variable formulary placement for Jardiance. Boehringer Ingelheim offers the Jardiance Savings Card program for commercially insured patients, which may reduce out-of-pocket cost to as low as $10 per 30-day supply. Medicare Part D beneficiaries are not eligible for manufacturer coupons but may qualify for the Extra Help (Low Income Subsidy) program.

Pharmacy Options in Vermont for Empagliflozin

Chain pharmacies with Vermont locations, including CVS, Rite Aid, and Kinney Drugs, all carry Jardiance in both the 10 mg and 25 mg strengths. Independent pharmacies in Montpelier, Burlington, and St. Johnsbury generally stock at least the 10 mg strength. For rural Vermont patients in areas such as the Northeast Kingdom or the Upper Connecticut River Valley, mail-order pharmacy through your insurer's preferred vendor or a VIPPS-accredited online pharmacy is a practical option.

503A compounding pharmacies licensed in Vermont may prepare patient-specific formulations of empagliflozin when a commercially manufactured product is not clinically appropriate. This pathway applies when a patient requires a dose not available in the commercial 10 mg or 25 mg tablet, or when a patient has a documented allergy to an excipient in the branded tablet. The 503A compounding pharmacy must hold a Vermont pharmacy license, and the prescription must be patient-specific with a valid prescriber relationship. 503B outsourcing facilities may not legally ship to Vermont patients without a patient-specific prescription from a Vermont-licensed prescriber.

GoodRx pricing for empagliflozin 10 mg (30 tablets) in Vermont ZIP codes ranges from approximately $520 to $580 at retail without insurance as of mid-2025, reflecting the brand-only market. No FDA-approved generic empagliflozin was available in the US market as of the publication date of this article; Boehringer Ingelheim's patent protection for Jardiance extends into the late 2020s.

Labs Required Before Starting Jardiance in Vermont

No provider should initiate empagliflozin without a current renal function panel. The FDA label specifies that empagliflozin is not recommended to improve glycemic control in adults with type 2 diabetes when eGFR is persistently <30 mL/min/1.73m2, though it may still be prescribed for the cardiovascular or CKD indication at lower eGFR levels down to 20 mL/min/1.73m2 [7].

The minimum lab panel before starting includes:

• Serum creatinine with calculated eGFR (CKD-EPI 2021 equation preferred)
• Serum potassium (diuretic effect can affect electrolyte balance, especially in patients on ACE inhibitors or ARBs)
• Serum glucose or HbA1c (for the diabetes indication)
• Urine albumin-to-creatinine ratio (UACR) if CKD is the indication

A urinalysis is not required before starting but may be clinically appropriate if the patient has a history of recurrent urinary tract infections, since SGLT2 inhibitors increase glucosuria and may raise the risk of urogenital infections by 1.5 to 2 times baseline rates, per pooled phase III trial data [8].

Blood pressure measurement (in-person or home reading submitted at the telehealth visit) is worth documenting before initiation. Empagliflozin produces a modest systolic blood pressure reduction of approximately 3 to 5 mmHg, which is a benefit for most hypertensive patients but may require medication adjustment in patients already on aggressive antihypertensive regimens.

Transferring an Existing Jardiance Prescription to Vermont

If you are relocating to Vermont or establishing care with a new Vermont provider, transferring your Jardiance prescription is straightforward. Vermont law and federal DEA regulations allow pharmacies to transfer non-controlled substance prescriptions between licensed pharmacies without restriction on the number of transfers, provided refills remain on the original prescription.

To transfer: contact your new Vermont pharmacy with the name, address, and phone number of your previous pharmacy and your prescription number. The receiving pharmacist contacts the sending pharmacy to verify remaining refills and transfer the prescription. This takes 24 to 48 hours in most cases. If the original prescription has no refills remaining, the receiving pharmacy will contact your prescriber for a new Vermont-issued prescription.

If your previous prescriber is not licensed in Vermont, a Vermont-licensed provider must issue a new prescription. A telehealth visit is the most efficient path in that situation. The new provider will want your previous prescription bottle or pharmacy records to verify your established dose.

Managing Jardiance Long-Term in Vermont

Once you are established on empagliflozin, ongoing management is straightforward for most patients. Annual labs (BMP or CMP, HbA1c for diabetes patients, UACR for CKD patients) are standard. Your provider may want to recheck renal function at four to eight weeks after initiation and after any dose change or addition of another diuretic or nephrotoxin.

Sick-day management deserves a specific instruction: hold empagliflozin on the day of any planned procedure requiring contrast dye, on any day with significant vomiting or inability to maintain oral hydration, and in the 48 hours before elective surgery. The risk of euglycemic diabetic ketoacidosis (DKA), a rare but serious adverse event, is elevated during periods of carbohydrate restriction, prolonged fasting, or acute illness [9]. Patients should carry a card noting they are on an SGLT2 inhibitor so emergency providers can check ketones even if blood glucose appears normal.

The CREDENCE trial (N=4,401) demonstrated that canagliflozin (a related SGLT2 inhibitor) reduced the risk of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death by 30% relative to placebo in patients with type 2 diabetes and CKD (HR 0.70 to 95% CI 0.59 to 0.82, P=0.00001) [10]. Empagliflozin's EMPA-KIDNEY trial (N=6,609) replicated this class effect, reducing the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [11]. Vermont nephrologists now routinely add empagliflozin to the regimens of CKD patients who previously would have received only ACE inhibitors or ARBs.